The impact of Aldehyde dehydrogenase 1 expression on prognosis for metastatic colon cancer

Journal of Surgical Research

Volumn 192, Issue 1, 2014, Pages 82-89

  Fitzgerald, Timothy L ^a   Rangan, Swathi ^a   Dobbs, Larry ^a   Starr, Shane ^a   Sigounas, George ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Cancer stem cells; Colon cancer; Survival

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 1; PARAFFIN; ALDEHYDE DEHYDROGENASE; ALDH1B1 PROTEIN, HUMAN; ALDH1L1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER STEM CELL; CANCER SURGERY; CANCER SURVIVAL; CELL ISOLATION; COLORECTAL CANCER; CONTROLLED STUDY; CRYPT CELL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; CELL CULTURE; COLON TUMOR; ENZYMOLOGY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; MULTICELLULAR SPHEROID; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SECONDARY;

ALDEHYDE DEHYDROGENASE; CELLS, CULTURED; COLONIC NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASTIC STEM CELLS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SPHEROIDS, CELLULAR; TUMOR MARKERS, BIOLOGICAL;

EID: 84921772093     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2014.05.054     Document Type: Article

References (37)

1. Kelley RK, Van Bebber SL, Phillips KA, Venook AP. Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer. J Natl Compr Canc Netw: JNCCN 2011;9:13.
2. Ricci-Vitiani L, Fabrizi E, Palio E, De Maria R. Colon cancer stem cells. J Mol Med (Berl) 2009;87:1097.
3. Boman BM, Huang E. Human colon cancer stem cells: a new paradigm in gastrointestinal oncology. J Clin Oncol: Official J Am Soc Clin Oncol 2008;26:2828.
4. Langan RC, Mullinax JE, Raiji MT, et al. Colorectal cancer biomarkers and the potential role of cancer stem cells. J Cancer 2013;4:241.
5. Huntly BJ, Gilliland DG. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer 2005;5: 311.
6. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445:106.
7. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445:111.
8. Shmelkov SV, Butler JM, Hooper AT, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest 2008;118:2111.
9. Chu P, Clanton DJ, Snipas TS, et al. Characterization of a subpopulation of colon cancer cells with stem cell-like properties. Int J Cancer J Int du Cancer 2009;124:1312.
10. Huang EH, Wicha MS. Colon cancer stem cells: implications for prevention and therapy. Trends Mol Med 2008;14:503.
11. Huang EH, Hynes MJ, Zhang T, et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 2009;69:3382.
12. Barker N, van Es JH, Kuipers J, et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007;449:1003.
13. Charafe-Jauffret E, Ginestier C, Birnbaum D. Cancer stem cells: just sign here! Cell Cycle 2010;9:229.
14. Deng S, Yang X, Lassus H, et al. Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PloS one 2010;5:e10277.
15. Wu A, Luo W, Zhang Q, et al. Aldehyde dehydrogenase 1, a functional marker for identifying cancer stem cells in human nasopharyngeal carcinoma. Cancer Lett 2013;330:181.
16. Rasheed ZA, Matsui W. Biological and clinical relevance of stem cells in pancreatic adenocarcinoma. J Gastroenterol Hepatol 2012;27(Suppl 2):15.
17. Charafe-Jauffret E, Ginestier C, Iovino F, et al. Aldehyde dehydrogenase 1-positivecancer stemcellsmediatemetastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res: Official J Am Assoc Cancer Res 2010;16:45.
18. Langan RC, Mullinax JE, Ray S, et al. A pilot study assessing the potential role of non-CD133 colorectal cancer stem cells as biomarkers. J Cancer 2012;3:231.
19. Coco C, Zannoni GF, Caredda E, et al. Increased expression of CD133 and reduced dystroglycan expression are strong predictors of poor outcome in colon cancer patients. J Exp Clin Cancer Res: CR 2012;31:71.
20. Kitamura H, Torigoe T, Hirohashi Y, et al. Prognostic impact of the expression of ALDH1 and SOX2 in urothelial cancer of the upper urinary tract. Mod Pathol: Official J United States Can Acad Pathol Inc 2013;26:117.
21. Cammareri P, Lombardo Y, Francipane MG, Bonventre S, Todaro M, Stassi G. Isolation and culture of colon cancer stem cells. Methods Cell Biol 2008;86:311.
22. Kreso A, O'Brien CA. Colon cancer stem cells. Curr Protoc Stem Cell Biol; 2008. Chapter 3:Unit 3 1.
23. Shi H, Hayes M, Kirana C, et al. TUFM is a potential new prognostic indicator for colorectal carcinoma. Pathology 2012;44:506.
24. Bao B, Ahmad A, Azmi AS, Ali S, Sarkar FH. Overview of cancer stem cells (CSCs) and mechanisms of their regulation: implications for cancer therapy. Curr Protoc Pharmacol; 2013. Chapter 14:Unit 14 25.
25. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983.
26. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105.
27. Ohata H, Ishiguro T, Aihara Y, et al. Induction of the stemlike cell regulator CD44 by Rho kinase inhibition contributes to the maintenance of colon cancer-initiating cells. Cancer Res 2012;72:5101.
28. Shenoy A, Butterworth E, Huang EH. ALDH as a marker for enriching tumorigenic human colonic stem cells. Methods Mol Biol 2012;916:373.
29. Yu Y, Kanwar SS, Patel BB, et al. MicroRNA-21 induces stemness by downregulating transforming growth factor beta receptor 2 (TGFbetaR2) in colon cancer cells. Carcinogenesis 2012;33:68.
30. Piscuoglio S, Lehmann FS, Zlobec I, et al. Effect of EpCAM, CD44, CD133 and CD166 expression on patient survival in tumours of the ampulla of Vater. J Clin Pathol 2012;65:140.
31. Lugli A, Iezzi G, Hostettler I, et al. Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. Br J Cancer 2010;103:382.
32. Horst D, Kriegl L, Engel J, Kirchner T, Jung A. Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. Cancer Invest 2009;27:844.
33. Li CY, Li BX, Liang Y, et al. Higher percentage of CD133+ cells is associated with poor prognosis in colon carcinoma patients with stage IIIB. J Transl Med 2009;7:56.
34. Wu XS, Xi HQ, Chen L. Lgr5 is a potential marker of colorectal carcinoma stem cells that correlates with patient survival. World J Surg Oncol 2012;10:244.
35. Horst D, Scheel SK, Liebmann S, et al. The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer. J Pathol 2009;219:427.
36. Horst D, Kriegl L, Engel J, Kirchner T, Jung A. CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 2008;99:1285.
37. Horst D, Kriegl L, Engel J, Jung A, Kirchner T. CD133 and nuclear beta-catenin: the marker combination to detect high risk cases of low stage colorectal cancer. Eur J Cancer 2009; 45:2034.